MedTrace Logo

Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer

NCT06068738 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2024-09-26

No results posted yet for this study

Summary

EXCYTE-1 is a multicentre, prospective observational study to investigate the relationship between ex vivo drug response (EVDR), measured in ovarian tumour-derived samples using high content imaging, and actual patient clinical response.

Patients with newly diagnosed or relapsed/refractory epithelial ovarian carcinoma, that present with malignant effusions (ascites or pleural effusions), will be enrolled in the study before starting their initial or next treatment line.

Enrolled patients will be asked to provide ascites, peripheral blood and fresh tumour tissue if available. Samples will be shipped to the sponsor laboratory and their response to standard of care drugs evaluated ex vivo.

Participants will:

* provide samples during routine clinical procedures
* agree that data about their medical history, diagnosis and health status at the following timepoints are collected: at signature of the consent form, at the time samples are provided, at start of the therapy, upon completion of the therapy, regularly after completion of the therapy

Conditions

  • Epithelial Ovarian Cancer

Interventions

OTHER

Biological sample collection

Collection of ascites, blood and fresh tumour tissues (if available)

Sponsors & Collaborators

  • AGO Research GmbH

    collaborator INDUSTRY

  • Exscientia AI Limited

    lead INDUSTRY

Principal Investigators

  • Nikolaus Krall, Dr. · Exscientia GmbH

Eligibility

Min Age
18 Years
Max Age
125 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-14
Primary Completion
2024-08-14
Completion
2024-08-14

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068738 on ClinicalTrials.gov